Diagnosis of epidermolysis bullosa acquisita: Multicentre comparison of different assays for serum anti-type VII collagen reactivity

Maike Marleen Holtsche; Nina Van Beek; Takashi Hashimoto; Giovanni Di Zenzo; Detlef Zillikens; Catherine Prost-Squarcioni; Matthias Titeux; Alain Hovnanian; Enno Schmidt; Stephanie Goletz

doi:10.2340/00015555-3774

Diagnosis of epidermolysis bullosa acquisita: Multicentre comparison of different assays for serum anti-type VII collagen reactivity

Maike Marleen Holtsche, Nina Van Beek, Takashi Hashimoto, Giovanni Di Zenzo, Detlef Zillikens, Catherine Prost-Squarcioni, Matthias Titeux, Alain Hovnanian, Enno Schmidt, Stephanie Goletz^*

^*Corresponding author for this work

Abstract

Epidermolysis bullosa acquisita is a pemphigoid disease characterized by autoantibodies against type VII collagen. This study compared the sensitivity and specificity of 6 diagnostic assays: type VII collagen noncollagenous domains enzyme-linked immunoassay (NC1/2 ELISA) (MBL, Nagoya, Japan); type VII collagen NC1 ELISA (Euroimmun, Lübeck, Germany); indirect immunofluorescence (IF) microscopy test based on the expression of recombinant NC1 in a human cell line (NC1 BIOCHIP®; Euroimmun); full-length recombinant type VII collagen ELISA; immunoblotting with full-length type VII collagen in the extract of human dermis; and immunoblotting with recombinant NC1. Immunoblotting with recombinant NC1 showed a sensitivity of 93.1% and specificity of 100%, followed by NC1 BIOCHIP® (sensitivity, 89.1%; specificity, 100%), immunoblotting with human dermis (sensitivity, 87.1%; specificity 100%), NC1-ELISA (sensitivity 82.2%; specificity 98.6%), NC1/NC2 ELISA (sensitivity 88.1%; specificity 93.3%), and full-length type VII collagen ELISA (sensitivity 80.2%; specificity 93.8%).

Original language	English
Article number	adv00420
Journal	Acta Dermato-Venereologica
Volume	101
Issue number	3
Pages (from-to)	adv00420
ISSN	0001-5555
DOIs	https://doi.org/10.2340/00015555-3774
Publication status	Published - 2021

Research Areas and Centers

Academic Focus: Center for Infection and Inflammation Research (ZIEL)
Centers: Center for Research on Inflammation of the Skin (CRIS)

DFG Research Classification Scheme

2.21-05 Immunology
2.22-19 Dermatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2340/00015555-3774

Cite this

Holtsche, M. M., Van Beek, N., Hashimoto, T., Di Zenzo, G., Zillikens, D., Prost-Squarcioni, C., Titeux, M., Hovnanian, A., Schmidt, E., & Goletz, S. (2021). Diagnosis of epidermolysis bullosa acquisita: Multicentre comparison of different assays for serum anti-type VII collagen reactivity. Acta Dermato-Venereologica, 101(3), adv00420. Article adv00420. https://doi.org/10.2340/00015555-3774

@article{50a11e6ce627442ab4066d0b00e5285e,

title = "Diagnosis of epidermolysis bullosa acquisita: Multicentre comparison of different assays for serum anti-type VII collagen reactivity",

abstract = "Epidermolysis bullosa acquisita is a pemphigoid disease characterized by autoantibodies against type VII collagen. This study compared the sensitivity and specificity of 6 diagnostic assays: type VII collagen noncollagenous domains enzyme-linked immunoassay (NC1/2 ELISA) (MBL, Nagoya, Japan); type VII collagen NC1 ELISA (Euroimmun, L{\"u}beck, Germany); indirect immunofluorescence (IF) microscopy test based on the expression of recombinant NC1 in a human cell line (NC1 BIOCHIP{\textregistered}; Euroimmun); full-length recombinant type VII collagen ELISA; immunoblotting with full-length type VII collagen in the extract of human dermis; and immunoblotting with recombinant NC1. Immunoblotting with recombinant NC1 showed a sensitivity of 93.1% and specificity of 100%, followed by NC1 BIOCHIP{\textregistered} (sensitivity, 89.1%; specificity, 100%), immunoblotting with human dermis (sensitivity, 87.1%; specificity 100%), NC1-ELISA (sensitivity 82.2%; specificity 98.6%), NC1/NC2 ELISA (sensitivity 88.1%; specificity 93.3%), and full-length type VII collagen ELISA (sensitivity 80.2%; specificity 93.8%).",

author = "Holtsche, {Maike Marleen} and {Van Beek}, Nina and Takashi Hashimoto and {Di Zenzo}, Giovanni and Detlef Zillikens and Catherine Prost-Squarcioni and Matthias Titeux and Alain Hovnanian and Enno Schmidt and Stephanie Goletz",

year = "2021",

doi = "10.2340/00015555-3774",

language = "English",

volume = "101",

pages = "adv00420",

journal = "Acta Dermato-Venereologica",

issn = "0001-5555",

number = "3",

}

Holtsche, MM , Van Beek, N, Hashimoto, T, Di Zenzo, G, Zillikens, D, Prost-Squarcioni, C, Titeux, M, Hovnanian, A, Schmidt, E & Goletz, S 2021, 'Diagnosis of epidermolysis bullosa acquisita: Multicentre comparison of different assays for serum anti-type VII collagen reactivity', Acta Dermato-Venereologica, vol. 101, no. 3, adv00420, pp. adv00420. https://doi.org/10.2340/00015555-3774

TY - JOUR

T1 - Diagnosis of epidermolysis bullosa acquisita: Multicentre comparison of different assays for serum anti-type VII collagen reactivity

AU - Holtsche, Maike Marleen

AU - Van Beek, Nina

AU - Hashimoto, Takashi

AU - Di Zenzo, Giovanni

AU - Zillikens, Detlef

AU - Prost-Squarcioni, Catherine

AU - Titeux, Matthias

AU - Hovnanian, Alain

AU - Schmidt, Enno

AU - Goletz, Stephanie

PY - 2021

Y1 - 2021

N2 - Epidermolysis bullosa acquisita is a pemphigoid disease characterized by autoantibodies against type VII collagen. This study compared the sensitivity and specificity of 6 diagnostic assays: type VII collagen noncollagenous domains enzyme-linked immunoassay (NC1/2 ELISA) (MBL, Nagoya, Japan); type VII collagen NC1 ELISA (Euroimmun, Lübeck, Germany); indirect immunofluorescence (IF) microscopy test based on the expression of recombinant NC1 in a human cell line (NC1 BIOCHIP®; Euroimmun); full-length recombinant type VII collagen ELISA; immunoblotting with full-length type VII collagen in the extract of human dermis; and immunoblotting with recombinant NC1. Immunoblotting with recombinant NC1 showed a sensitivity of 93.1% and specificity of 100%, followed by NC1 BIOCHIP® (sensitivity, 89.1%; specificity, 100%), immunoblotting with human dermis (sensitivity, 87.1%; specificity 100%), NC1-ELISA (sensitivity 82.2%; specificity 98.6%), NC1/NC2 ELISA (sensitivity 88.1%; specificity 93.3%), and full-length type VII collagen ELISA (sensitivity 80.2%; specificity 93.8%).

AB - Epidermolysis bullosa acquisita is a pemphigoid disease characterized by autoantibodies against type VII collagen. This study compared the sensitivity and specificity of 6 diagnostic assays: type VII collagen noncollagenous domains enzyme-linked immunoassay (NC1/2 ELISA) (MBL, Nagoya, Japan); type VII collagen NC1 ELISA (Euroimmun, Lübeck, Germany); indirect immunofluorescence (IF) microscopy test based on the expression of recombinant NC1 in a human cell line (NC1 BIOCHIP®; Euroimmun); full-length recombinant type VII collagen ELISA; immunoblotting with full-length type VII collagen in the extract of human dermis; and immunoblotting with recombinant NC1. Immunoblotting with recombinant NC1 showed a sensitivity of 93.1% and specificity of 100%, followed by NC1 BIOCHIP® (sensitivity, 89.1%; specificity, 100%), immunoblotting with human dermis (sensitivity, 87.1%; specificity 100%), NC1-ELISA (sensitivity 82.2%; specificity 98.6%), NC1/NC2 ELISA (sensitivity 88.1%; specificity 93.3%), and full-length type VII collagen ELISA (sensitivity 80.2%; specificity 93.8%).

UR - http://www.scopus.com/inward/record.url?scp=85103130698&partnerID=8YFLogxK

U2 - 10.2340/00015555-3774

DO - 10.2340/00015555-3774

M3 - Journal articles

C2 - 33686442

AN - SCOPUS:85103130698

SN - 0001-5555

VL - 101

SP - adv00420

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

IS - 3

M1 - adv00420

ER -

Diagnosis of epidermolysis bullosa acquisita: Multicentre comparison of different assays for serum anti-type VII collagen reactivity

Abstract

Research Areas and Centers

DFG Research Classification Scheme

UN SDGs

Access to Document

Other files and links

Fingerprint

EXC 2167: Precision Medicine in Chronic Inflammation (PMI)

CRU 303: Pemphigoid Diseases - Molecular Pathways and their Therapeutic Potential

Cite this

Diagnosis of epidermolysis bullosa acquisita: Multicentre comparison of different assays for serum anti-type VII collagen reactivity

Abstract

Research Areas and Centers

DFG Research Classification Scheme

UN SDGs

Access to Document

Other files and links

Fingerprint

Projects

EXC 2167: Precision Medicine in Chronic Inflammation (PMI)

CRU 303: Pemphigoid Diseases - Molecular Pathways and their Therapeutic Potential

Cite this